Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8133893 | PRAGMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(4 years from now) |
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8133893 | ANGELINI PHARMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6607748 | ANGELINI PHARMA | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
Jun, 2020
(3 years ago) | |
US7829120 | ANGELINI PHARMA | Trazodone composition for once a day administration |
Mar, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Feb 02, 2013 |
Market Authorisation Date: 02 February, 2010
Treatment: Method of treating depression
Dosage: TABLET, EXTENDED RELEASE;ORAL